Yahoo · Sep 18, 2026
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
NYSE · WST
West Pharmaceutical Services, Inc.
Healthcare · Medical - Instruments & Supplies
$362.31
Down-$4.44 (-1.21%)
Updated Sep 20, 2026, 12:05 PM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 19.61B
- P/E ratio
- 40.07
- Dividend yield
- 0.30%
- 52-week range
- $223.83 – $386.00
- Volume
- 1.46M
- Avg. volume
- 696.99K
Price performance
WST price history
1M range · 19 trading sessions · Daily adjusted prices
WST closed at $362.31 after 19 trading sessions, up 2.54% for the selected period.
- Last close
- $362.31
- Period change
- +2.54%
- Period low
- $336.94
- Period high
- $366.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $366.59 | $366.86 | $359.52 | $362.31 | 1.46M |
| Sep 17, 2026 | $366.20 | $368.795 | $363.14 | $366.60 | 474.06K |
| Sep 16, 2026 | $363.11 | $367.33 | $361.0616 | $362.01 | 621.05K |
| Sep 15, 2026 | $355.02 | $370.67 | $354.65 | $365.00 | 981.89K |
| Sep 14, 2026 | $349.94 | $356.61 | $345.15 | $355.20 | 625.56K |
| Sep 11, 2026 | $343.87 | $351.96 | $341.675 | $346.23 | 541.79K |
| Sep 10, 2026 | $333.57 | $344.92 | $331.99 | $344.25 | 653.06K |
| Sep 9, 2026 | $337.63 | $340.475 | $336.10 | $336.94 | 473.17K |
| Sep 8, 2026 | $335.51 | $342.34 | $334.04 | $337.75 | 580.99K |
| Sep 4, 2026 | $339.76 | $342.67 | $339.76 | $339.97 | 364.08K |
| Sep 3, 2026 | $343.97 | $345.50 | $338.445 | $342.73 | 242.27K |
| Sep 2, 2026 | $338.85 | $346.00 | $338.85 | $342.63 | 323.73K |
| Sep 1, 2026 | $341.83 | $342.6675 | $337.85 | $338.65 | 482.81K |
| Aug 31, 2026 | $336.25 | $342.59 | $335.51 | $341.11 | 615.6K |
| Aug 28, 2026 | $344.51 | $345.87 | $336.13 | $337.47 | 496.41K |
| Aug 27, 2026 | $350.00 | $352.05 | $346.08 | $346.09 | 365.99K |
| Aug 26, 2026 | $347.97 | $353.12 | $346.25 | $349.92 | 440.22K |
| Aug 25, 2026 | $353.75 | $354.78 | $348.22 | $348.48 | 383.76K |
| Aug 24, 2026 | $350.48 | $354.48 | $348.84 | $353.32 | 473.31K |
Latest WST news
The latest Smart Investors Daily articles mentioning WST.
Stock researchCompany · Overview
WST research
Overview
Company profile and research snapshot.
Company profile
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $335.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Aug 3, 2026 | Citigroup | Buy | — |
| Jul 27, 2026 | Evercore ISI Group | Outperform | — |
| Jul 13, 2026 | BNP Paribas | Outperform | — |
| Jul 9, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Yahoo · Sep 16, 2026
Is West Pharmaceutical Services Stock Outperforming the Nasdaq?
West Pharmaceutical Services has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.
Yahoo · Sep 15, 2026
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
